analyst-ratings

Ignite It
1 min read • September 20, 2019

MKM Partners Initiates Coverage On Aurora Cannabis with Sell Rating, Announces $5 Price Target

Ignite It
1 min read • September 19, 2019

MKM Partners Initiates Coverage Neutral Ratings On Tilray, Cronos, Sell Rating On Aurora Cannabis; Cronos Price Target C$14, Tilray Target $34, Aurora Target C$5

Ignite It
1 min read • September 16, 2019

UPDATE: Stifel On Aurora Cannabis Also Believes Co’s ‘financing efforts will be challenged against the backdrop of overwhelmingly negative investor sentiment towards the sector, damaged credibility, and limited catalysts near-term’

Ignite It
1 min read • September 16, 2019

UPDATE: Stifel Downgrades Aurora Cannabis To Sell, Lowers Target To C$5 As Firm Notes Q4 Earnings Point ‘to a less robust in-market performance and difficulty to continue positioning for the larger global opportunity’

Ignite It
1 min read • September 16, 2019

Stifel Downgrades Aurora Cannabis to Sell, Lowers Price Target to $5

Ignite It
3 min read • August 30, 2019

Bank Of America: There’s Still A Canadian Cannabis Bottleneck

Ignite It
2 min read • August 15, 2019

Cannabis Short Sellers Clean Up After Tilray’s Earnings Miss

Ignite It
1 min read • August 13, 2019

UPDATE: PiperJaffray Also Believes Co. ‘has significant potential growth opportunities with CBD products in the US, including through its pending acquisition of the Lord Jones brand’

Ignite It
1 min read • August 13, 2019

Piper Jaffray Initiates Coverage On Aurora Cannabis with Neutral Rating, Announces $7 Price Target

Ignite It
2 min read • July 18, 2019

Bank Of America Downgrades Aurora Cannabis, Concerned About Cash Burn

Ignite It
1 min read • July 18, 2019

Bank of America Downgrades Aurora Cannabis to Neutral

Ignite It
1 min read • July 17, 2019

Ladenburg Thalmann Initiates Coverage On Aurora Cannabis with Buy Rating, Announces $9 Price Target

Browse By Channels

 After-Hours Center
 Analyst Color
 Analyst Ratings
 Andy Barr
 Asia
 Asset Sales
 Be Your Own Boss
 Binary Options
 Biotech
 Bonds
 Broad U.S. Equity ETFs
 Buybacks
 california cannabis
 Cannabis
 cannabis earnings
 cannabis farms
 cannabis study
 Christopher Dillis
 CNBC
 Commodities
 Congress cannabis
 Congress hemp
 Contracts
 Crowdsourcing
 Cryptocurrency
 Currency ETFs
 Dividends
 Downgrades
 Earnings
 Earnings Beats
 Earnings Misses
 Econ #s
 Economics
 Education
 Emerging Market ETFs
 Emerging Markets
 Entertainment
 Entrepreneurship
 Equities
 ESG
 ETFs
 Eurozone
 Events
 Exclusives
 Fast Money
 FDA
 Federal Reserve
 Financial Advisors
 Financing
 Fintech
 first quarter earnings
 Forex
 Futures
 Gaming
 General
 Global
 Government
 Guidance
 Health Care
 Hedge Funds
 hemp bill
 hemp legalization
 hemp regulation
 Hot
 illegal cannabis farms
 Initiation
 Insider Trades
 Insurance
 Interview
 intoxicating hemp-derived products
 Intraday Update
 IPOs
 James Comer
 Large Cap
 Latin America
 Legal
 Long Ideas
 M&A
 Macro Economic Events
 Macro Notification
 Management
 marijuana
 Market Summary
 Market-Moving Exclusives
 Markets
 Media
 Mid Cap
 Movers
 Movers & Shakers
 New ETFs
 News
 Offerings
 Opinion
 Options
 Penny Stocks
 Personal Finance
 Politics
 Pre-Market Outlook
 Press Releases
 Previews
 Price Target
 Psychedelics
 Psychology
 Real Estate
 Regulations
 REIT
 Reiteration
 Rescheduling
 Restaurants
 Retail Sales
 Reviews
 Rumors
 SEC
 Sector ETFs
 Short Ideas
 Short Sellers
 Signals
 Small Business
 Small Cap
 Small Cap Analysis
 Social Media
 Specialty ETFs
 Sports
 Sports Betting
 Startups
 Stock Split
 Success Stories
 Taxes
 Tech
 Technicals
 THC
 Top Stories
 Topics
 Trading Ideas
 Travel
 UC Berkeley Cannabis Research Center
 unlicensed cannabis
 Upgrades
 WIIM

Join the Cannabis Revolution

Ready to access the most aggressive cannabis intelligence platform? Get started with IGNITE IT today.